Get the Stockscreener App
0.4675
1.37%
-0.0065
After Hours:
.46
-0.0075
-1.60%
Moleculin Biotech Inc stock is traded at $0.4675, with a volume of 1.22M.
It is down -1.37% in the last 24 hours and up +28.50% over the past month.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
See More
Previous Close:
$0.474
Open:
$0.4775
24h Volume:
1.22M
Relative Volume:
0.36
Market Cap:
$23.14M
Revenue:
-
Net Income/Loss:
$-29.77M
P/E Ratio:
-0.0306
EPS:
-15.2954
Net Cash Flow:
$-24.23M
1W Performance:
-3.05%
1M Performance:
+28.50%
6M Performance:
-41.55%
1Y Performance:
-80.84%
1-Day Range:
$0.4602
$0.4985
1-Week Range:
$0.4602
$0.525
52-Week Range:
$0.25
$3.6499
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.4675 | 23.46M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Resumed | H.C. Wainwright | Buy |
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Visual analytics tools that track Moleculin Biotech Inc. performanceTrade Volume Summary & Fast Entry and Exit Trade Plans - newser.com
Can machine learning forecast Moleculin Biotech Inc. recovery2025 Market Trends & Risk Adjusted Swing Trade Ideas - newser.com
Will Moleculin Biotech Inc. stock go up soonQuarterly Profit Review & Safe Investment Capital Preservation Plans - newser.com
Why Moleculin Biotech Inc. stock is rated strong buyWeekly Trade Analysis & Safe Entry Point Identification - newser.com
Top chart patterns to watch in Moleculin Biotech Inc.July 2025 News Drivers & Technical Analysis for Trade Confirmation - newser.com
Can Moleculin Biotech Inc. stock deliver surprise earnings beatJuly 2025 Retail & Risk Controlled Stock Pick Alerts - newser.com
Is Moleculin Biotech Inc. stock attractive after correction2025 Year in Review & Fast Gain Stock Trading Tips - newser.com
Real time social sentiment graph for Moleculin Biotech Inc.2025 Big Picture & Entry and Exit Point Strategies - newser.com
Is Moleculin Biotech Inc. stock overvalued by current metrics2025 Fundamental Recap & Short-Term High Return Strategies - newser.com
Technical signs of recovery in Moleculin Biotech Inc.Weekly Gains Report & Stepwise Entry/Exit Trade Alerts - newser.com
Moleculin Biotech Inc. stock momentum explainedJuly 2025 WrapUp & Accurate Trade Setup Notifications - newser.com
Analyzing Moleculin Biotech Inc. with multi timeframe chartsWeekly Profit Summary & Long-Term Capital Growth Strategies - newser.com
How to escape a deep drawdown in Moleculin Biotech Inc.2025 Big Picture & Free Daily Entry Point Trade Alerts - newser.com
Can Moleculin Biotech Inc. (MOL) stock stage a strong rebound this quarter - newser.com
How to build a dashboard for Moleculin Biotech Inc. stockInflation Watch & Safe Entry Point Identification - newser.com
Will earnings trigger a reversal in Moleculin Biotech Inc.Trade Performance Summary & Low Drawdown Investment Ideas - newser.com
Can Moleculin Biotech Inc. (MOL) stock hold up in economic slowdown2025 Trading Volume Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Moleculin Biotech Secures $6 Million Through Warrant Agreement - MSN
Moleculin Biotech (NASDAQ:MBRX) Stock Rating Lowered by Wall Street Zen - Defense World
MBRXMoleculin Reports Second Quarter 2025 Financial Results and Highlights - ADVFN
Moleculin receives notice of intent to grant new European patent for Annamycin - MSN
What drives Moleculin Biotech Inc MOL stock priceFibonacci Extensions & High Profit Trading Plans - earlytimes.in
What analysts say about Moleculin Biotech Inc stockVolume Analysis Techniques & Low Risk Capital Growth Plans - earlytimes.in
What Technical Indicators Signal for GOCL Corporation Limited Next MonthAutomated Trading Signals & Discover Top Gainers in Every Sector - earlytimes.in
Moleculin Biotech Inc Stock Analysis and ForecastSupport Level Holds & Grow Generational Wealth With Ease - Early Times
What analysts say about Kekrops SA KE1 stockAnalyst Downgrades & Superior Growth Trading - Early Times
Moleculin Biotech announces issuance of Canadian patent covering Annamycin - Yahoo Finance
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moleculin Biotech Inc Stock (MBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):